EQS-Adhoc: PharmaSGP Holding SE: Delisting of PharmaSGP shares from Frankfurt Stock Exchange effective upon the expiry of August 11, 2025
|
EQS-Ad-hoc: PharmaSGP Holding SE / Key word(s): Delisting Ad-hoc announcement pursuant to Article 17 of the Regulation (EU) No. 596/2024 PharmaSGP Holding SE: Delisting of PharmaSGP shares from Frankfurt Stock Exchange effective upon the expiry of August 11, 2025 Gräfelfing, August 6, 2025 – The Management Board of PharmaSGP Holding SE (“PharmaSGP”) has been informed today about the decision of the management of the Frankfurt Stock Exchange that the revocation of the admission of the shares of PharmaSGP to trading on the regulated market of the Frankfurt Stock Exchange under ISIN DE000A2P4LJ5, as applied for by PharmaSGP, will become effective upon the expiry of August 11, 2025. PharmaSGP will also make applications to the other stock exchanges on which shares of PharmaSGP are traded in the open market to terminate such trading and inclusion in the open market, if possible, with the expiry of August 11, 2025, or shortly thereafter. The revocation of the admission to trading (delisting) takes place in the context of the delisting offer by FUTRUE GmbH dated July 14, 2025, the offer period of which will expire on August 11, 2025. As already announced in the ad hoc notification dated June 10, 2025, as part of a delisting agreement with FUTRUE GmbH dated June 10, 2025, PharmaSGP has undertaken, among other things, subject to customary conditions, to support the delisting of PharmaSGP by applying for the revocation of the admission of all PharmaSGP shares to trading on the regulated market of the Frankfurt Stock Exchange before the expiry of the offer period of the delisting offer by FUTRUE GmbH.
CONTACT
ABOUT PHARMASGP HOLDING SE The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan®, Formigran®, Spalt® and Kamol®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of €118.8 million at an adjusted EBITDA margin of 31.3%. In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP’s product offering, increase PharmaSGP’s European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.
End of Inside Information
06-Aug-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | PharmaSGP Holding SE |
| Lochhamer Schlag 1 | |
| 82166 Gräfelfing | |
| Germany | |
| E-mail: | ir@pharmasgp.com |
| Internet: | https://pharmasgp.com |
| ISIN: | DE000A2P4LJ5 |
| WKN: | A2P4LJ |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Tradegate Exchange |
| EQS News ID: | 2180372 |
| End of Announcement | EQS News Service |
|
|
2180372 06-Aug-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 62,57 | 63,25 | 65,34 | 85,82 | 101,10 | 118,74 | 135,00 | |
| EBITDA1,2 | 22,82 | 14,73 | 18,49 | 26,93 | 34,10 | 37,05 | 38,00 | |
| EBITDA-Margin3 | 36,47 | 23,29 | 28,30 | 31,38 | 33,73 | 31,20 | 28,15 | |
| EBIT1,4 | 22,42 | 14,25 | 14,92 | 17,68 | 24,64 | 27,64 | 28,00 | |
| EBIT-Margin5 | 35,83 | 22,53 | 22,83 | 20,60 | 24,37 | 23,28 | 20,74 | |
| Net Profit (Loss)1 | 16,71 | 10,64 | 10,69 | 11,95 | 16,40 | 19,54 | 19,85 | |
| Net-Margin6 | 26,71 | 16,82 | 16,36 | 13,92 | 16,22 | 16,46 | 14,70 | |
| Cashflow1,7 | 17,63 | 15,46 | 12,24 | 24,71 | 26,64 | 24,88 | 25,10 | |
| Earnings per share8 | 1,39 | 0,89 | 0,89 | 1,00 | 1,37 | 1,65 | 1,66 | |
| Dividend per share8 | 0,00 | 0,00 | 0,45 | 0,49 | 1,36 | 0,51 | 0,51 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PricewaterhouseCoopers
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| PharmaSGP Holding | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2P4LJ | DE000A2P4LJ5 | SE | 386,40 Mio € | 19.06.2020 | Halten | 8FWH4FC2+4G |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 18,61 | 23,88 | 0,78 | 25,18 | 14,81 | 15,53 | 3,25 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 1,36 | 0,51 | 0,51 | 1,59% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 25.06.2025 | 15.05.2025 | 25.09.2025 | 13.11.2025 | 30.04.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +2,57% | +0,00% | +0,00% | +0,00% | +1,59% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
